Search results
Results from the WOW.Com Content Network
Currently, if the hepatic adenoma is >5 cm, increasing in size, symptomatic lesions, has molecular markers associated with HCC transformation, rising level of liver tumor markers such as alpha fetoprotein, the patient is a male, or has a glycogen storage disorder, the adenoma is recommended to be surgically removed. [7]
The liver is a common site for metastatic disease because of its rich, dual blood supply (the liver receives blood via the hepatic artery and portal vein). Metastatic tumors in the liver are 20 times more common than primary tumors. In 50% of all cases the primary tumor is of the gastrointestinal tract; other common sites include the breast ...
Liver tumor types by relative incidence in adults in the United States (liver cancers in dark red color). [14] The most frequent liver cancer, accounting for approximately 75% of all primary liver cancers, is hepatocellular carcinoma (HCC). [15] HCC is a cancer formed by liver cells, known as hepatocytes, that become malignant. In terms of ...
Barcelona Clinic Liver Cancer (BCLC) Staging System. The prognosis of HCC is affected by the staging of the tumor, the liver's function due to the effects of chronic liver disease and cirrhosis as well as the person's physical performance status. [48] A number of staging classifications for HCC are available.
The usual markers for liver disease – aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase – are often normal or only slightly elevated. FLC often does not produce alpha fetoprotein (AFP), a widely used marker for conventional hepatocellular carcinoma.
For example, tumor markers like Ki-67 can be used to choose form of treatment or in prognostics but are not useful to give a diagnosis, while other tumor markers have the opposite functionality. Therefore it's important to follow the guidelines of the specific tumor marker. Tumor markers are mainly used in clinical medicine to support a ...
Liver angiosarcoma usually presents with vague and non-specific symptoms such as abdominal pain, abdominal distension (which are the two most common symptoms, occurring in around 60% of individuals [3]), weight loss, fatigue or abdominal masses and liver disease like symptoms such as fever, malaise, anorexia and vomiting.
Two areas in particular that are receiving attention as surrogate markers include circulating tumor cells (CTCs) [45] [46] and circulating miRNAs. [47] [48] Both these markers are associated with the number of tumor cells present in the blood, and as such, are hoped to provide a surrogate for tumor progression and metastasis. However ...